Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.